Antimicrobial Medications: History, Mechanisms, and Resistance

Antimicrobial Drugs: Overview, Targets, and Resistance

Introduction

Antimicrobial medications are essential tools in modern medicine, enabling the treatment of infectious diseases caused by bacteria, viruses, fungi, and parasites. This guide covers the history, development, characteristics, mechanisms of action, and resistance associated with antimicrobial drugs.

• Antibiotics: Drugs derived from natural sources or synthesized to kill or inhibit bacteria.

• Antimicrobial drugs: Broader category including antibiotics and drugs targeting viruses, fungi, and parasites.

• Resistance: The ability of microorganisms to withstand the effects of drugs, posing a major public health challenge.

Significance:

• Medical relevance: Guides effective prescription and reduces resistance.

• Public health relevance: Resistance is a major global health threat.

• Research relevance: Informs development of new drugs and therapies.

Section 20.1 – History and Development of Antimicrobial Medications

Introduction

The development of antimicrobial medications revolutionized the treatment of infectious diseases. Key historical milestones highlight the discovery and improvement of these drugs.

• Paul Ehrlich (early 1900s): Searched for a "magic bullet"—a compound that could kill microbes without harming the host.

• Alexander Fleming (1928): Discovered penicillin from the mold Penicillium.

• Antibiotics discovered: Many were isolated from soil bacteria, such as Streptomyces.

• Development today: Involves screening natural products, modifying existing drugs, and designing synthetic drugs.

Example: Penicillin was the first widely used antibiotic, dramatically reducing deaths from bacterial infections.

Section 20.2 – Characteristics of Antimicrobial Medications

Introduction

Antimicrobial drugs are evaluated based on their selectivity, spectrum of activity, pharmacokinetics, and adverse effects. These properties determine their clinical usefulness and safety.

• Selectivity toxicity: Drug targets microbial structures/processes not found in humans, minimizing harm to the host.

• Toxic dose vs. therapeutic dose: The therapeutic index is the ratio of toxic dose to effective dose; higher values indicate safer drugs.

• Antimicrobial action: Drugs may be bacteriostatic (inhibit growth) or bactericidal (kill bacteria).

• Spectrum of activity:

  • Broad-spectrum: Active against a wide range of microbes; higher risk of disrupting normal flora and causing side effects.

  • Narrow-spectrum: Target specific microbes; lower risk of side effects.

• Combinations: Drugs may act synergistically (enhanced effect) or antagonistically (reduced effect).

• Distribution & excretion: Pharmacokinetics affect drug levels in tissues and duration of action.

• Adverse effects: Allergic reactions, toxicity, and dysbiosis (disruption of normal microbiota).

Example: Broad-spectrum antibiotics like tetracycline can treat multiple infections but may cause gastrointestinal upset due to disruption of gut flora.

Section 20.3 – Mechanisms of Action of Antibacterial Medications

Introduction

Antibacterial drugs target essential bacterial processes, including cell wall synthesis, protein synthesis, nucleic acid synthesis, metabolic pathways, and membrane integrity.

• Cell Wall Inhibitors (β-lactams):

  • Block synthesis of peptidoglycan, weakening cell wall and causing lysis.

  • Examples: Penicillins, cephalosporins, carbapenems.

  • Selective toxicity: Human cells lack peptidoglycan.

• Protein Synthesis Inhibitors:

  • Bind to bacterial ribosomes (70S), inhibiting translation.

  • Examples: Aminoglycosides, tetracyclines, macrolides.

  • Limitation: May affect mitochondrial ribosomes (similar to bacterial ribosomes).

• Nucleic Acid Inhibitors:

  • Fluoroquinolones block DNA gyrase.

  • Rifamycins block RNA polymerase.

• Metabolic Pathway Inhibitors:

  • Block synthesis of essential metabolites (e.g., folic acid).

  • Examples: Sulfonamides, trimethoprim.

• Membrane Inhibitors:

  • Disrupt bacterial cell membranes, causing leakage and cell death.

  • Example: Polymyxins.

Example: β-lactam antibiotics are highly effective against actively growing bacteria due to their action on cell wall synthesis.

Section 20.4 – Antibacterial Medications Targeting Specific Bacteria

Introduction

Certain bacteria, such as Mycobacterium tuberculosis, have unique features that require specialized drugs for effective treatment.

• Mycobacterium tuberculosis: Has a waxy cell wall (mycolic acids), making it resistant to many drugs.

• First-line drugs: Isoniazid, ethambutol, pyrazinamide, rifampin.

• Lengthy treatment: Due to slow growth and persistence of bacteria.

Example: TB treatment requires multiple drugs over several months to prevent resistance and ensure eradication.

Section 20.5 – Resistance to Antimicrobial Medications

Introduction

Resistance to antimicrobial drugs is a growing problem, driven by genetic changes and the spread of resistance genes among microbes.

• Acquired resistance: Results from mutation or gene transfer (horizontal gene transfer).

• Mechanisms:

  • Drug-inactivating enzymes (e.g., β-lactamases)

  • Alteration of drug target (e.g., ribosomal changes)

  • Decreased uptake (porin mutations)

  • Increased elimination (efflux pumps)

  • Bypass pathways

• Spread of resistance: Horizontal gene transfer (conjugation, transformation, transduction) and rapid selection under drug pressure.

Example: Methicillin-resistant Staphylococcus aureus (MRSA) is resistant to multiple antibiotics due to acquired resistance mechanisms.

Section 20.6 – Antiviral Medications

Introduction

Antiviral drugs target specific stages of the viral life cycle, but options are limited due to the reliance of viruses on host cell machinery.

• Antiviral strategies:

  • Prevent entry/uncoating (fusion inhibitors, amantadine)

  • Block viral nucleic acid synthesis (acyclovir, AZT)

  • Prevent integration (HIV integrase inhibitors)

  • Prevent assembly/release (protease inhibitors, neuraminidase inhibitors)

• Limitation: Fewer drug targets due to dependence on host cell processes.

Example: Acyclovir selectively inhibits herpesvirus DNA polymerase, sparing host enzymes.

Section 20.7 – Antifungal Medications

Introduction

Antifungal drugs target unique components of fungal cells, such as ergosterol in the cell membrane, but selective toxicity is limited due to similarities with human cells.

• Target: Fungal membranes (ergosterol, not cholesterol)

• Examples: Amphotericin B, azoles, echinocandins

• Limitations: Fewer selective targets; toxicity is a concern.

Example: Amphotericin B binds to ergosterol, disrupting fungal cell membranes.

Section 20.8 – Antiprotozoan & Antihelminthic Medications

Introduction

Drugs targeting protozoa and helminths interfere with metabolic processes or neuromuscular function, but development is challenging due to similarities with human cells.

• Protozoa: Drugs interfere with DNA synthesis or metabolic pathways.

• Helminths: Drugs affect neuromuscular function or energy metabolism.

• Challenge: Parasites are eukaryotic, limiting selective drug targets.

Example: Metronidazole is used to treat protozoan infections by disrupting DNA synthesis.

Summary Table: Mechanisms of Action of Antimicrobial Drugs

Drug Class	Target	Examples	Selective Toxicity
β-lactams	Cell wall synthesis	Penicillins, cephalosporins	High (humans lack peptidoglycan)
Aminoglycosides, tetracyclines	Protein synthesis (ribosome)	Streptomycin, doxycycline	Moderate (mitochondrial ribosomes affected)
Fluoroquinolones	DNA synthesis	Ciprofloxacin	High
Rifamycins	RNA synthesis	Rifampin	High
Polymyxins	Cell membrane	Polymyxin B	Low (toxicity)
Azoles	Fungal membrane (ergosterol)	Fluconazole	Moderate
Antivirals	Viral enzymes	Acyclovir, AZT	High (virus-specific)

Key Equations

• Therapeutic Index: $\text{Therapeutic Index} = \frac{\text{Toxic Dose}}{\text{Therapeutic Dose}}$

Additional info:

• Antimicrobial resistance is accelerated by misuse and overuse of antibiotics.

• Horizontal gene transfer includes conjugation (plasmid exchange), transformation (uptake of free DNA), and transduction (bacteriophage-mediated transfer).

• Designing new antibiotics requires balancing spectrum, toxicity, and resistance potential.